Amarin Corp Plc (AMRN)

[Chabojilo]

These arguments that we pose seem very clear and level-headed to me, it isn't that we are all boxed into a group consensus and are unable to see the other side.

The other side compared Niacin and Fenofibrate studies that are not 1:1 applicable to Mixed Dyslipidemics. The Omega 3 studies pose other concerns such as LDL-C raising, even if Trigs had been lowered.

The stubbornness must stem somewhat from the embarrassment of having approved Niacin and Fenofibrate for Trig reduction and having them back-fire, so they go to the other extreme to try to rectify their mistake??

They are being extreme, as we all see the studies and the AACE chimes in to agree that Mixed Dys with Trigs over 200 and low HDL need to be treated with Omega 3s.

How many lives do we need to lose until REDUCE-IT is complete? What will the FDA say to those families who could have benefitted from Vascepa assuming the What If scenario is very positive for Outcomes benefits on V?